Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932690 | 0.79 | RXRA (0.47) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL24780428 | 0.79 | KRAS (0.35) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30932801 | 0.76 | RXRA (0.41) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30535663 | 0.75 | RXRA (0.48) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL29344497 | 0.73 | CYP4F2 (0.34) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL21243909 | 0.73 | RXRA (0.48) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL20437662 | 0.73 | RXRA (0.48) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL20437685 | 0.73 | RXRA (0.51) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL22723613 | 0.72 | RXRA (0.44) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL20438231 | 0.72 | RXRA (0.44) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622643-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112831-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |